Monte Rosa registers Phase 2 trial pairing MRT-2359 with apalutamide in prostate cancer
Monte Rosa Therapeutics has listed a new Phase 2 study testing its degrader MRT-2359 alongside apalutamide in castration-resistant prostate cancer, targeting 25 patients.
Monte Rosa Therapeutics registered one new trial this week.
- MRT-2359 in combination with apalutamide is being studied in a Phase 2, open-label trial called "MODeFIRe-1" for patients with castration-resistant prostate cancer, sponsored by Monte Rosa Therapeutics, Inc. This Phase 2, open-label, multicenter study is conducted in patients with castration-resistant prostate cancer.1 The study is recruiting, with an estimated enrollment of 25 participants, and its primary aim is to assess the PSA response rate of the combination as determined by PCWG4 criteria.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.